New IASLC Grading System for Pulmonary Adenocarcinoma Proposed

Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC

Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19

Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work

Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer

Lung Ambition Alliance: Stronger Together 

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Patient Advocate Comment: Amivantamab for Exon 20

Presidential Symposium Findings 

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Lung Cancer Screening Study in East Asia Successful at Identifying Early-Stage Disease